Gilbert Wagener
Directeur Technique/Scientifique/R&D chez PHARNEXT SCA
Profil
Gilbert Wagener is currently the Chief Medical Officer at Pharnext SA since 2023.
Prior to this, he held the same position at Cell2B - Advanced Therapeutics SA and Ixaka Ltd.
Dr. Wagener holds a doctorate from Erasmus University Rotterdam and Philipps University of Marburg, and an MBA from the University of Basel.
Postes actifs de Gilbert Wagener
Sociétés | Poste | Début |
---|---|---|
PHARNEXT SCA | Directeur Technique/Scientifique/R&D | 15/06/2023 |
Anciens postes connus de Gilbert Wagener
Sociétés | Poste | Fin |
---|---|---|
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Directeur Technique/Scientifique/R&D | - |
Formation de Gilbert Wagener
Philipps University of Marburg | Doctorate Degree |
University of Basel | Masters Business Admin |
Erasmus University Rotterdam | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PHARNEXT SCA | Health Technology |
Entreprise privées | 2 |
---|---|
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Health Technology |
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Health Technology |